Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AC676 in relapsed/refractory B-cell malignancies
NCT05780034Phase 1Recruiting
- Sponsor
- Accutar Biotechnology, Inc.
- Start
- Jun 2023
- Primary completion
- Mar 2026
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AC0676 in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL) and 4 more, sponsored by Accutar Biotechnology, Inc. Primary endpoints: Dose Limiting Toxicities at 4 weeks, Treatment-Emergent Adverse Events at 18 months and 2 more. Started Jun 2023; status: recruiting.
02
Drugs
AC0676
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)mantle cell lymphoma (MCL)follicular lymphoma (FL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05780034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05780034.